Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2023-06-08 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
关于变更注册地址、经营范围及修订《公司章程》的公告
Board/Management Information Classification · 95% confidence The document is an announcement from 广州市香雪制药股份有限公司 regarding changes to the company's registered address, business scope, and amendments to the company's articles of association. It states that these changes were approved by the board and will be submitted to the 2022 annual general meeting for approval. The document does not contain financial data, audit information, or detailed reports but is a formal announcement of corporate governance changes and amendments to company bylaws. This fits the category of Board/Management Information (MANG), which covers announcements of changes in company management or governance structure. The document length is short (1911 characters), and it is not a report or presentation but an official announcement of changes requiring shareholder approval.
2023-06-08 Chinese
第九届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It details decisions such as changes to the registered address, business scope, amendments to the company bylaws, and scheduling of the 2022 Annual General Meeting. The document includes voting results and states that these matters will be submitted to the 2022 Annual General Meeting for approval. There is no financial data or detailed report content; rather, it is a corporate governance announcement about board decisions and meeting arrangements. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2023-06-08 Chinese
公司章程（2023年6月）
Governance Information Classification · 100% confidence The document is titled as the "公司章程" (Company Articles or Articles of Association) of 广州市香雪制药股份有限公司, revised in June 2023. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, capital changes, shareholder meetings, and governance rules. It is a comprehensive governance document outlining the internal rules and structure of the company rather than a financial report or announcement. There is no indication that this is an annual report, audit report, earnings release, or any other financial or regulatory filing. The content matches the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-06-08 Chinese
关于对深圳证券交易所年报问询函回复的公告
Annual Report Classification · 95% confidence The document is a detailed announcement from 广州市香雪制药股份有限公司 responding to an inquiry letter from the Shenzhen Stock Exchange regarding the company's annual report. It discusses various risks, detailed financial and asset information, audit opinions, and evaluation reports related to fixed assets and construction projects. The content is extensive (15,000 characters) and includes substantive financial data, asset valuations, audit procedures, and management explanations. The document is not merely an announcement of a report but contains detailed financial and operational disclosures typical of an annual report. The presence of year-end asset values, impairment testing, audit opinions, and detailed financial disclosures aligns with the characteristics of an Annual Report (10-K). Therefore, the document should be classified as an Annual Report (10-K). FY 2022
2023-05-18 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "广州市香雪制药股份有限公司2023 年第一季度报告" which translates to "Guangzhou Xiangxue Pharmaceutical Co., Ltd. 2023 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the first quarter of 2023. The document explicitly states it is a quarterly report and is unaudited. The length of the document (13,086 characters) and the presence of comprehensive financial statements confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-27 Chinese
第九届董事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. It reports the approval of the company's 2023 first quarter report but does not contain the actual financial data or the report itself. It states that the detailed quarterly report is disclosed elsewhere (on a website). The document is short (589 characters) and serves as an announcement of the board's approval of the quarterly report, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than an Interim/Quarterly Report (IR).
2023-04-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.